3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
4
Tumor-Agnostic
3
Lymphoid
3
Thoracic
2
Other hematologic neoplasm
2
Other
1
Genitourinary
1
Conditions
Stomatitis
1
Neoplasms
1
Mucositis
1
Interventions
naloxegol
7
alvimopan
6
Radiotherapy
5
angiotensin I (1-7)
4
Cisplatin
4
tegaserod
3
Injections
3
RRx-001
2
Fibroblast Growth Factor 7
2
tempol
1
prucalopride
1
oxycodone naloxone combination
1
naldemedine
1
methylnaltrexone
1
linaclotide
1
licogliflozin
1
hydrated silica gel-based toothpaste
1
golotimod
1
brilacidin
1
apraglutide
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Water
1
Therapeutics
1
Testosterone Propionate
1
Robotic Surgical Procedures
1
Radiotherapy, Intensity-Modulated
1
Phenylephrine
1
Oxycodone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diphenhydramine
×
Other
×
Clear all
NCT02606994
2019-02-06
TPvsM
Oral Defense, LLC
Phase 2
Terminated
1 enrolled